Save up -80% on Coagulation Factor XIII A-Subunit (Recombinant)
Note: this is a drug discount program, not an insurance plan.
2018 Price of Tretten
* price without discount in nearest pharmacy. Price may vary.
We offer free Coagulation Factor XIII A-Subunit (Recombinant) coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your discount card in most local pharmacies to get a discount on Coagulation Factor XIII A-Subunit (Recombinant) every time. What are you waiting for? Claim your prescription drug card now!
Coagulation Factor XIII A-Subunit (Recombinant) volume of distribution
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Coagulation Factor XIII A-Subunit (Recombinant)
Coagulation Factor XIII A-Subunit (Recombinant) is a recombinant form of the A subunit of human coagulation factor XIII intravenously available as an A2 homodimer. Factor XIII is an endogenously available coagulation factor, and the final enzyme within the blood coagulation cascade. Within the body, FXIII circulates as a heterotetramer composed of 2 A-subunits and 2 B-subunits (A2B2). When activated by thrombin at the site of injury, the FXIII pro-enzyme is cleaved resulting in activation of the catalytic A-subunit and dissociation from its carrier B-subunit. As a result, the active transglutaminase from subunit A cross-links fibrin and other proteins resulting in increased mechanical strength and resistance to fibrinolysis of the fibrin clot which contributes to enhanced platelet and clot adhesion to injured tissue[A18581]. When supplied as the recombinant form, Coagulation Factor XIII A-Subunit (Recombinant) binds to free human FXIII B-subunit resulting in a heterotetramer (rA2B2) with a similar activity profile and half-life as the endogenously available form. In patients with congenital factor XIII A-subunit deficiency, this product (marketed as Tretten) is indicated for the routine prophylaxis of bleeding. In these patients, activated rFXIII has been shown to increase mechanical strength of fibrin clots, retard fibrinolysis, and to enhance platelet adhesion to the site of injury. Tretten is manufactured as an intracellular, soluble protein in yeast (Saccharomyces cerevisiae) production strain containing the episomal expression vector, pD16. It is subsequently isolated by homogenization of cells and purification by several chromatography steps, including hydrophobic interaction and ion exchange chromatography.
Coagulation Factor XIII A-Subunit (Recombinant) mechanism of action
Dosage forms of Coagulation Factor XIII A-Subunit (Recombinant)
Blood Coagulation Factor XIII (Synthetic Human A-Chain Precursor) Catridecacog
Indication of Coagulation Factor XIII A-Subunit (Recombinant)
For routine prophylaxis of bleeding in patients with congenital factor XIII A-Subunit deficiency.
Toxicity of Coagulation Factor XIII A-Subunit (Recombinant)
The most common adverse reactions reported in clinical trials ( 1%), were headache, pain in the extremities, injection site pain, and increase in fibrin D dimer levels. Due to the anti-clotting activity of this medication, thromboembolic complications may occur with its usage.
RX24 Drugs Disclaimer: before buying a Coagulation Factor XIII A-Subunit (Recombinant) on prescription, consult your healthcare provider. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.